Brookstone Capital Management raised its stake in shares of Axon Enterprise, Inc. (NASDAQ:AXON – Free Report) by 5.1% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 839 shares of the biotechnology company’s stock after acquiring an additional 41 shares during the period. Brookstone Capital Management’s holdings in Axon Enterprise were worth $263,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also bought and sold shares of the company. ICA Group Wealth Management LLC bought a new position in Axon Enterprise during the 4th quarter valued at about $26,000. First PREMIER Bank purchased a new stake in shares of Axon Enterprise during the 1st quarter valued at about $33,000. BKM Wealth Management LLC purchased a new stake in shares of Axon Enterprise during the 4th quarter valued at about $32,000. Rise Advisors LLC increased its position in shares of Axon Enterprise by 49.0% during the 1st quarter. Rise Advisors LLC now owns 143 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 47 shares during the last quarter. Finally, Key Financial Inc increased its position in shares of Axon Enterprise by 367.6% during the 4th quarter. Key Financial Inc now owns 159 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 125 shares during the last quarter. Institutional investors own 79.08% of the company’s stock.
Insider Buying and Selling
In related news, insider Jeffrey C. Kunins sold 43,668 shares of the firm’s stock in a transaction on Thursday, May 9th. The stock was sold at an average price of $309.94, for a total value of $13,534,459.92. Following the completion of the sale, the insider now directly owns 189,719 shares in the company, valued at $58,801,506.86. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In related news, insider Jeffrey C. Kunins sold 43,668 shares of the firm’s stock in a transaction on Thursday, May 9th. The stock was sold at an average price of $309.94, for a total value of $13,534,459.92. Following the completion of the sale, the insider now directly owns 189,719 shares in the company, valued at $58,801,506.86. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Julie A. Cullivan sold 993 shares of Axon Enterprise stock in a transaction on Friday, May 31st. The stock was sold at an average price of $281.72, for a total value of $279,747.96. Following the sale, the director now owns 4,553 shares of the company’s stock, valued at $1,282,671.16. The disclosure for this sale can be found here. Insiders sold a total of 89,447 shares of company stock worth $27,684,677 over the last three months. 5.70% of the stock is owned by insiders.
Analysts Set New Price Targets
Several equities research analysts have recently commented on AXON shares. Needham & Company LLC reaffirmed a “buy” rating and set a $400.00 price target on shares of Axon Enterprise in a research report on Tuesday, May 7th. JMP Securities reaffirmed a “market outperform” rating and set a $375.00 price target on shares of Axon Enterprise in a research report on Tuesday, May 7th. Argus started coverage on shares of Axon Enterprise in a research report on Wednesday, March 13th. They set a “buy” rating and a $380.00 price target for the company. JPMorgan Chase & Co. upped their price target on shares of Axon Enterprise from $330.00 to $365.00 and gave the company an “overweight” rating in a research report on Thursday, April 11th. Finally, StockNews.com lowered shares of Axon Enterprise from a “buy” rating to a “hold” rating in a report on Thursday, March 14th. Two equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Axon Enterprise currently has a consensus rating of “Moderate Buy” and a consensus target price of $335.27.
Get Our Latest Research Report on AXON
Axon Enterprise Stock Up 1.4 %
NASDAQ AXON opened at $293.18 on Wednesday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 2.55 and a current ratio of 2.91. The company has a market capitalization of $22.13 billion, a P/E ratio of 85.73 and a beta of 0.95. Axon Enterprise, Inc. has a one year low of $175.37 and a one year high of $329.87. The stock has a 50 day moving average price of $294.99 and a 200-day moving average price of $285.77.
Axon Enterprise (NASDAQ:AXON – Get Free Report) last issued its quarterly earnings results on Friday, May 10th. The biotechnology company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.95 by $0.20. The company had revenue of $460.74 million during the quarter, compared to the consensus estimate of $441.57 million. Axon Enterprise had a return on equity of 11.71% and a net margin of 15.60%. Axon Enterprise’s revenue was up 34.3% on a year-over-year basis. During the same period last year, the company earned $0.51 earnings per share. As a group, equities analysts predict that Axon Enterprise, Inc. will post 2.35 EPS for the current fiscal year.
About Axon Enterprise
Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.
Featured Stories
Want to see what other hedge funds are holding AXON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axon Enterprise, Inc. (NASDAQ:AXON – Free Report).
Receive News & Ratings for Axon Enterprise Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Axon Enterprise and related companies with MarketBeat.com’s FREE daily email newsletter.
